Component
Human plasma carnitine during valproate therapy
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In the patient observed when starting valproate, plasma carnitine fell during weeks 1-3 and recovered by weeks 3-5.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- One longitudinal initiation case plus ten long-term patients.
- limitations
- Suppressed synthesis and increased OCTN2 expression were proposed explanations, not directly measured human mechanisms.
- nutrient_topic
- L-Carnitine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnitine
- plain_language
- Drug-associated carnitine changes can evolve over time.
- primary_references
- Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22743351/ · DOI 10.1097/FTD.0b013e3182608e2f
L-Carnitine: synthesis, acyl-group transport, fuel selection and nutrient interactions (2026-09-19) · lines 282–288
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · One longitudinal initiation case plus ten long-term patients. · source_derived_draft · unverified_draft
## l-carnitine-valproate-timecourse Drug-associated carnitine changes can evolve over time. In the patient observed when starting valproate, plasma carnitine fell during weeks 1-3 and recovered by weeks 3-5. Model: One longitudinal initiation case plus ten long-term patients. Limitations: Suppressed synthesis and increased OCTN2 expression were proposed explanations, not directly measured human mechanisms. Evidence access: Primary abstract Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans. · 2012 · https://pubmed.ncbi.nlm.nih.gov/22743351/ · DOI 10.1097/FTD.0b013e3182608e2f
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.